Predicting Human Oral Bioavailability: Comparison of *in vivo* animal (rat, dog, and monkey) studies versus mechanistic *in vitro in vivo* extrapolation (IVIVE) based predictions

CERTARA
Simcyp

N Patel*, M Zhang, M Jamei

Simcyp Division, Certara UK Limited, Sheffield, UK. *Correspondence: nikunj.patel@Certara.com

Purpose

Identifying critical factors affecting bioavailability (F) and predicting the human oral bioavailability (F_{human}) before first-in-human trials are very important to prioritize and support drug discovery and development projects. At preclinical stage, animal *in vivo* pharmacokinetic studies and/or various *in vitro* measurements such as solubility and permeability (affecting absorption into the gut-wall), metabolism (first pass-elimination in gut-wall and liver) are conducted to understand/estimate the human oral bioavailability. Carefully collated dataset of 184 compounds by Musther et al. demonstrated no strong or predictive correlations between animal and human bioavailability for all species, individually and combined [1]. This comprehensive analysis showed that bioavailability estimated in animal studies are poorly reflecting that of humans. This raised a question if the mechanistic *in vitro* to *in vivo* extrapolation (IVIVE) commonly employed in the physiologically based pharmacokinetics (PBPK) modelling for human pharmacokinetics (PK) simulations can be used as an alternative to predict F_{human}. Here, we present the preliminary results of a proof-of-concept study we carried out to assess the utility of mechanistic IVIVE to predict F_{human}.

Figure 2. *Animal versus human and between animal species oral bioavailability (dotted trend line has unrestricted intercept while the solid black line has an intercept of zero)*

Name	Dose (mg)	F (Pred)	F (Obs)	LogP	MW	So (mg/mL)	Peff (cm/s)	HLM Clint (ul/min/mg)	fm3A4	MAD (mg)	fa	Fg	Fh
Nifedipine	20	0.486386	0.5	2.69	346.3	0.0177	0.000569144	141	0.94	68.1022263	1	0.720536	0.675033
acyclovir (high dose)	800	0.234581	0.2	-1.56	225.21	2.5	2.26464E-05	0.166	0	188.976286	0.23622	1	0.99306
acyclovir (low dose)	350	0.536185	0.52	-1.56	225.21	2.5	2.26464E-05	0.166	0	188.976286	0.539932	1	0.99306
Alprazolam	1	0.945569	0.92	2.12	308.8	0.013	0.000954773	3.69	0.67	57.4490283	1	0.995924	0.949439
cyclosporin (fed)	800	0.266007	0.2	2.96	1202	0.0066	0.00026521	94.53	1	257.542535	0.321928	0.865212	0.955018
Erythromycin	250	0.442127	0.355	2.5	733.9	0.04	2.39216E-05	32.8	1	826.716569	1	0.658252	0.671668
Fluconazole	65	0.996722	0.9	0.2	306.3	1.39	0.000357419	0.09	0	1678.5483	1	1	0.996722
Ibuprofen	200	1	0.9	3.23	206.27	0.021	0.000526528	93.22	0.14	3908.42216	1	0.975163	0.93494
itraconazole (fed)	200	0.477677	0.55	4.47	705.6	0.000189042	0.000985	1730	0.97	329.48297	1	0.981816	0.486524
metformin	500	0.708306	0.55	-1.43	129.16	1.38	4.10677E-05	1.662	0	378.318793	0.756638	1	0.936123
Metoprolol	50	0.502168	0.55	1.88	267.4	500	0.000242144	31.18	0.07	1380801.61	1	0.994083	0.505157
midazolam	15	0.284633	0.34	3.53	325.8	0.00987	0.000637285	392	0.98	1133.24948	1	0.557778	0.510297
moxifloxacin	100	0.92988	0.82	0.832	401.4	1.146	0.000192396	5.36	1	15151653.5	1	1	0.92988
omeprazole	40	0.479227	0.49	2.23	345.4	0.359	0.000324	303.64	0.13	1398.07355	1	0.914636	0.523954
phenobarbital	100	0.996979	1	1.47	232.24	1.11	0.000117409	0.125	0	715.700147	1	1	0.996979
phenytoin	322	0.708293	0.78	2.47	252.28	0.032	0.000486	4.639	0	235.191452	0.730408	1	0.969722
Quinidine	261.8	0.762958	0.7	2.81	324.4	0.14	0.0003468	24.17	0.96	1257442.54	1	0.949465	0.803566
Ranitidine	150	0.894261	0.544	0.27	314.4	43.39	0.000037	3	0	8526511.63	1	1	0.894261
Rifampin	600	0.985194	0.948	4.01	823	1.4	0.000243587	2.84	0	2683090209	1	1	0.985194
rosiglitazone	4	0.928281	0.99	2.88	357.4	0.015	0.00065	289.9	0	1201.78022	1	1	0.928281
rosuvastatin	40	0.472056	0.2	2.4	481.54	0.088	9.57194E-06	17	0	27.153409	0.678835	1	0.695392
sildenafil	50	0.537195	0.404	2.97	474.58	0.004	7.55092E-05	98	0.82	67.5538345	1	0.667205	0.805142
tacrolimus	5	0.104005	0.155	3.3	804.031	0.008	4.59198E-06	54.8	0.63	1.90405693	0.380811	0.273289	0.999358
triazolam	0.25	0.610002	0.53	2.42	343.2	0.005	0.000954773	45.21	0.9	67.719466	1	0.936897	0.651088
warfarin	15	0.93638	0.94	2.7	308.3	0.002	0.000299502	7.66	0	14.1130798	0.940872	1	0.995226
zolpidem	50	0.660637	0.662	2.42	307.39	0.073	0.001097489	89.69	0.63	6243.63622	1	0.91671	0.720661

Table 1. *List of 25 compounds with observed and predicted human oral bioavailability with physicochemical, permeability and metabolism inputs and calculated f_a, F_g and F_H from mechanistic IVIVE*

Figure 1. *Mechanistic IVIVE predicted versus observed F_{human} (dotted trend line has unrestricted intercept while the solid black line has an intercept of zero)*

Materials and Methods

We have chosen 25 compounds out of the 184 compounds of Musther et al. that exist in the Simcyp compound library or a published PBPK model is available. Simcyp library compounds were chosen for this preliminary study as the required *in vitro* and physchem data were readily available. Fraction absorbed into the gut-wall (f_a) was estimated using the method proposed by Matsumura et al. [2]. This method requires solubility of a given drug in FaSSIF (3mM bile salts and pH 6.5) for fasted oral dose and FeSSIF (15mM bile salts and pH 5) for fed state dosing and effective permeability (P_{eff}). FaSSIF and FeSSIF solubility were predicted using the Glomme et al. [3] QSAR method as implemented within the Simcyp Simulator predicting partitioning of the drug in bile micelles ($K_{micelle:water}$) using the molecule's lipophilicity (LogP). Permeability was either scaled from *in vitro* P_{app} to human P_{eff} using the regression equations available in the Simcyp Simulator or estimated from polar surface area (PSA) and hydrogen bond donor (HBD) using QSAR method reported by Winiwarter *et al.* [4]. First-pass liver metabolism (F_H) was predicted using well-stirred liver model. The unbound human liver microsomal (HLM) $CL_{int,u}$ values for a given drug were obtained from the Simcyp Simulator compound database or published PBPK models. Fraction of drug metabolised by CYP3A4 ($f_{m,3A4}$) with respect to the total unbound HLM $CL_{int,u}$ was obtained from the Simcyp database or from Yau *et al* [5]. Fraction of drug escaping first-pass gut-wall metabolism (F_g) was calculated using the 'Qgut' model [6] where the $f_{m,3A4}$ values used to determine the CYP3A4 contribution in the gut metabolism. Then F_{human} was calculated using $F_{human,pred} = f_a * F_g * F_H$. Some of the $CL_{int,u}$ and $f_{m,3A4}$ values were informed or verified using clinical data which improves $F_{human,pred}$. To compare the predictions against the data solely measured in vitro, $CL_{int,u}$ values measured in *in-vitro* assays were obtained from literature [5,7,8] and bottom-up IVIVE predictions were compared to observed F_{human}.

Results

Predicted F_{human} values using IVIVE (with verified/refined *in vitro* $CL_{int,u}$ from the Simcyp library and literature *in vitro* $CL_{int,u}$) compared with the observed F_{human} from are reported in Figure 1 A and B, respectively. Figure 2 A, B and C shows the rat, dog and monkey F versus F_{human} for the same drugs where data were available in individual species. The IVIVE based predictions showed a good correlation with F_{human} close to line of identity with R^2 of more than 0.8 while animal predicted F showed relatively poorer correlation with human F. Figure 2D also demonstrates poor between-species (here rat and dog) correlation for animal F.

Conclusions

The preliminary analysis of 25 drugs, which spans various BCS and BDDCS classes and diverse chemical nature (Log P range -1.6 to 4.8; MW 129 to 1202; PSA 37.6 to 279; HBD 0 to 5), showed mechanistic IVIVE predictions of human oral bioavailability are significantly better compared to the animals based predictions (Table 1). Using high quality *in vitro* data improves the IVIVE approach predictions, which in turn can reduce, refine and replace animal use in the research where there is known poor predictions in humans. We will further expand the compound database to investigate the approach for a wider dataset.

References

[1] Musther et al. Eur J Pharm Sci. 2014 Jun 16;57:280-91.
[2] Matsumura et al. J Pharm Sci. 2018 Sep;107(9):2489-2496.
[3] Glomme et al. J Pharm Sci. 2005 Jan;94(1):1-16.
[4] Winiwarter et al. J Med Chem. 1998 Dec 3;41(25):4939-49.
[5] Yau et al. Biopharm Drug Dispos. 2017 Apr;38(3):163-186.
[6] Yang et al. Curr Drug Metab. 2007 Oct;8(7):676-84.
[7] Wood et al. Drug Metab Dispos. 2017 Nov;45(11):1178-1188.
[8] Riley et al. Drug Metab Dispos. 2005 Sep;33(9):1304-11.